VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 272, Issue 6 41-6, 1997, Pages

  Sirois, Martin G ^a   Edelman, Elazer R ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Endothelial cells; Inflammation; Platelet activating factor antagonist; Vascular endothelial growth factor

Indexed keywords

EVANS BLUE; MITOGENIC AGENT; PROTEIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BLOOD VESSEL PERMEABILITY; CATTLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYNTHESIS; THIN LAYER CHROMATOGRAPHY; THROMBOCYTE AGGREGATION;

EID: 0030756944     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1997.272.6.h2746     Document Type: Article

References (20)

1. Berse, B., L. F. Brown, L. Van de Water, H. F. Dvorak, and D. R. Senger. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol. Biol. Cell 3: 211-220, 1992.
2. Bligh, E. G., and W. J. Dyer. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917, 1959.
3. Braquet, P., B. Spinnewyn, M. Braquet, R. M. Bourgain, J. E. Taylor, D. Nunez, and K. Drieu. BN 52021 and related compounds: a new series of highly specific PAF-acether receptor antagonists isolated from Ginkgo biloba. Blood Vessels 16: 559-572, 1985.
4. Braquet, P., L. Touqui, T. Y. Shen, and B. B. Vargaftig. Perspectives in platelet-activating factor research. Pharmacol. Rev. 39: 97-145, 1987.
5. 2+ and von Willebrand factor release in human endothelial cells. Am. J. Pathol. 138: 213-221, 1991.
6. Bussolino, F., and G. Camussi. Platelet-activating factor produced by endothelial cells. A molecule with autocrine and paracrine properties. Eur. J. Biochem. 229: 327-337, 1995.
7. Camussi, G., F. Mariano, L. Biancone, A. De Martino, B. Bussolati, G. Montrucchio, and P. S. Tobias. Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial cells and endothelial cells stimulated with lipopolysaccharide. J. Immunol. 155: 316-324, 1995.
8. Camussi, G., G. Montrucchio, E. Lupia, A. De Martino, L. Perona, M. Arese, A. Vercellone, A. Toniolo, and F. Bussolino. Platelet-activating factor stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J. Immunol. 154: 6492-6501, 1995.
9. Chander, C. L., A. R. Moore, F. M. Desa, D. W. Howat, and D. A. Willoughby. Anti-inflammatory effects of endothelin-1. J. Cardiovasc. Pharmacol. 13, Suppl. 5: S218-S219, 1989.
10. 2+-dependent translocation domain with homology to PKC and GAP. Cell 65: 1043-1049, 1991.
11. Collins, P. D., D. T. Connolly, and T. J. Williams. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br. J. Pharmacol. 109: 195-199, 1993.
12. Connolly, D. T., D. M. Heuvelman, R. Nelson, J. V. Olander, B. L. Eppley, J. J. Delfino, N. R. Siegel, R. M. Limgruber, and J. Feder. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84: 1470-1478, 1989.
13. Cunningham, S. A., M. N. Waxham, P. M. Arrate, and T. A. Brock. Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of the phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding. J. Biol. Chem. 270: 20254-20257, 1995.
14. Dejana, E., M. Corada, and M. G. Lampugnani. Endothelial cell-to-cell junctions. FASEB J. 9: 910-918, 1995.
15. Dillon, P. K., and W. N. Duran. Effect of platelet-activating factor in microvascular permselectivity: dose-response relations and pathways of action in the hamster cheek pouch microcirculation. Circ. Res. 62: 732-740, 1988.
16. Dvorak, H. F., L. F. Brown, M. Detmar, and A. M. Dvorak. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146: 1029-1039, 1995.
17. Evans, T. W., K. F. Chung, D. F. Rogers, and P. J. Barnes. Effect of platelet-activating factor on airway vascular permeability: possible mechanisms. J. Appl. Physiol. 63: 479-484, 1987.
18. Ferrara, N., K. Houck, L. Jakeman, and D. W. Leung. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. 13: 18-32, 1992.
19. Gomez-Cambronero, J., S. Velasco, J. M. Mato, and M. Sanchez-Crespo. Modulation of lyso-platelet activating factor: acetyl-CoA acetyltransferase from rat splenic microsomes. The role of cyclic AMP-dependent protein kinase. Biochim. Biophys. Acta 845: 516-519, 1985.
20. Hack, N., B. J. Margolis, A. Ullrich, J. Schlessinger, and K. L. Skorecki. Distinct structural specificities for functional coupling of the epidermal growth factor receptor to calcium-signalling versus phospholipase A2 responses. Biochem. J. 275: 563-567, 1991.